

CLAIMS

We Claim:

1. A method of inhibiting binding of interleukin-4 (IL-4) to an IL-4 Receptor (IL-4R), said method comprising contacting an IL-4R with an antibody to IL-4R, wherein said antibody inhibits binding of IL-4 to the IL-4R,
 - wherein the antibody is reactive with an IL-4R selected from the group consisting of:
 - a) a human IL-4R comprising amino acids 1 to 800 of Figures 4A-4C;
 - b) a soluble human IL-4R comprising amino acids 1 to 207 of Figure 4A;
 - c) a murine IL-4R comprising amino acids 1 to 785 of Figures 2A-2C; and
 - d) a soluble murine IL-4R comprising amino acids 1 to 208 of Figure 2A.
2. A method of claim 1, wherein the antibody is a monoclonal antibody.
3. A method of claim 1, wherein the antibody is reactive with a soluble human IL-4R, wherein the amino acid sequence of said soluble human IL-4R consists of amino acids 1 to 207 of Figure 4A.
4. A method of claim 3, wherein the antibody is a monoclonal antibody.
5. A method of claim 1, wherein the antibody inhibits binding of IL-4 to IL-4R on a cell.
6. A method of claim 2, wherein the monoclonal antibody inhibits binding of IL-4 to IL-4R on a cell.
7. A method of claim 3, wherein the antibody inhibits binding of IL-4 to IL-4R on a cell.
8. A method of claim 4, wherein the monoclonal antibody inhibits binding of IL-4 to IL-4R on a cell.
9. An antibody that is immunoreactive with a mammalian IL-4 receptor (IL-4R) selected from the group consisting of a murine IL-4R protein comprising amino acids 1 to 785 of Figures 2A-2C and a human IL-4R protein comprising amino acids 1 to 800 of Figures 4A-4C.